🚀 **OCGN is on the rise after major FDA win and June announcements!** 🚀Hey everyone, get ready—OCugen (NASDAQ: OCGN) just dropped three big June announcements that could take this small-cap stock soaring: (Has more than doubled in value over the last 3 months)1️⃣ FDA Approves Phase 2/3 Stargardt TrialWhat happened? On June 16, the FDA gave the green light for Ocugen’s Phase 2/3 trial of OCU410ST, a gene therapy for Stargardt disease (ABCA4-related retinopathies).Why it matters:Rare Pediatric & Orphan Drug Designations already in place → could lead to priority review vouchers and a faster path to approval.Clinical development sped up: 2-3 years sooner than expected.51 patients will be enrolled (34 treated vs. 17 controls) with a single subretinal injection—OCugen's first real shot at stopping this blinding disease. (globenewswire.com)2️⃣ Exclusive Korea License for RP Gene Therapy (OCU400)Announced on June 5Deal highlights:$11 million upfront + near-term milestones$150 million+ in sales milestones over the first decade25% royalties on net salesOcugen keeps manufacturing & supply → big potential if the Korean market takes off (globenewswire.com)3️⃣ BIO International Convention SpotlightDate: June 11News: Ocugen landed a presentation spot at the 2025 BIO International Convention (June 16–19 in Boston).Impact: Major biotech stage → exposure to top investors, potential partner buzz, and media attention right when clinical momentum is strong (globenewswire.com)🚀 Why OCGN Could Take OffFaster timeline thanks to FDA's quick approvalMultiple regulatory designations = less risk and hidden value (priority vouchers could be worth $100 M+!)Diverse revenue streams: licensing deals + future gene therapy salesClinical updates soon: Phase 2/3 enrollment should start soon, with early results possible in 12-18 monthsBottom Line: June has transformed OCGN from a small-cap promise to a gene therapy leader for blindness. If you're looking for a true penny-stock moonshot riding the biotech wave, OCGN is one to watch! 🚀Disclaimer: Not a suggestion to buy. Do your own homework!
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
